Products & Services
Omega Laboratories Limited has been supplying its expertise to the
Canadian pharmaceutical industry for more than sixty years.
FDA PAI is completed for new aseptic facility. The first injectable ANDA approval is received for the U.S. market.
Launch of commercial batches for the Canadian market from the new aseptic facility.
August 29th, 2016,
is acquired by Tokyo-based
Nichi-Iko Pharmaceutical Co.
October 1st, 2014, Sagent Pharmaceuticals Inc, a specialty pharmaceutical company, acquires Omega Laboratories Limited.
Initiation of a significant expansion project for a new injectable manufacturing plant, a new quality-control laboratory and additional office space.
High containment facility opens and launch of cytotoxic molecules.
New agreements with several large international partners for marketing and distribution of Omega’s products for international markets.
Significant investment into injectable manufacturing infrastructure and product development team. Transformation into a manufacturer of generic injectable drugs.
Acquisition of Ondée Laboratories, makers and suppliers of sclerotherapy products.
Acquisition of Hamon Laboratories and its injectable product manufacturing facility in Montreal.
Omega Laboratories is established in Montreal and dedicated to offer a complete allergy service (diagnostic and desensibilization therapy).
Connect with Us on